BR112013002375B1 - Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto - Google Patents
Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto Download PDFInfo
- Publication number
- BR112013002375B1 BR112013002375B1 BR112013002375-9A BR112013002375A BR112013002375B1 BR 112013002375 B1 BR112013002375 B1 BR 112013002375B1 BR 112013002375 A BR112013002375 A BR 112013002375A BR 112013002375 B1 BR112013002375 B1 BR 112013002375B1
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- cancer
- pyrimidine
- amino
- Prior art date
Links
- 0 *c1nc(NC(C(C#N)=C2)=O)c2cn1 Chemical compound *c1nc(NC(C(C#N)=C2)=O)c2cn1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37094610P | 2010-08-05 | 2010-08-05 | |
| US61/370946 | 2010-08-05 | ||
| PCT/US2011/044807 WO2012018540A1 (en) | 2010-08-05 | 2011-07-21 | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013002375A2 BR112013002375A2 (pt) | 2016-05-24 |
| BR112013002375B1 true BR112013002375B1 (pt) | 2020-05-12 |
Family
ID=45559737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013002375-9A BR112013002375B1 (pt) | 2010-08-05 | 2011-07-21 | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8987267B2 (https=) |
| EP (1) | EP2600719B1 (https=) |
| JP (1) | JP5512894B2 (https=) |
| KR (1) | KR101434841B1 (https=) |
| CN (1) | CN103200822B (https=) |
| AU (1) | AU2011286282B2 (https=) |
| BR (1) | BR112013002375B1 (https=) |
| CA (1) | CA2807498C (https=) |
| DK (1) | DK2600719T3 (https=) |
| EA (1) | EA022527B1 (https=) |
| ES (1) | ES2525866T3 (https=) |
| IL (1) | IL224555A (https=) |
| MX (1) | MX2013001427A (https=) |
| NZ (1) | NZ606281A (https=) |
| PL (1) | PL2600719T3 (https=) |
| PT (1) | PT2600719E (https=) |
| WO (1) | WO2012018540A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807498C (en) * | 2010-08-05 | 2017-02-07 | Temple University-Of The Commonwealth System Of Higher Education | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
| WO2014031571A1 (en) * | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| WO2014151682A1 (en) | 2013-03-14 | 2014-09-25 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| KR20170032244A (ko) | 2014-07-26 | 2017-03-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도 |
| CN104447739B (zh) * | 2014-11-07 | 2016-02-17 | 郑州泰基鸿诺药物科技有限公司 | 一种氘代Palbociclib衍生物、制备方法及应用 |
| CN104496983B (zh) | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| CN104478874B (zh) * | 2014-12-08 | 2016-03-02 | 新发药业有限公司 | 一种帕博赛布的制备方法 |
| CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
| CN105111205B (zh) * | 2015-09-12 | 2017-01-04 | 山东罗欣药业集团股份有限公司 | 一种帕博西尼的制备方法 |
| EP3556758B1 (en) | 2016-12-16 | 2024-07-17 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | 1,2-dihydro-1,6-naphthyridin-2-one derivatives as cdk4/6 inhibitors |
| WO2019161224A1 (en) | 2018-02-15 | 2019-08-22 | GiraFpharma LLC | Heterocyclic compounds as kinase inhibitors |
| KR102286701B1 (ko) * | 2018-09-28 | 2021-08-06 | 재단법인 대구경북첨단의료산업진흥재단 | 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| TWI818930B (zh) * | 2018-11-12 | 2023-10-21 | 美商昂可諾法治療股份有限公司 | 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途 |
| US20220002293A1 (en) * | 2018-11-12 | 2022-01-06 | Onconova Therapeutics, Inc. | 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders |
| WO2020140055A1 (en) * | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| WO2020140053A1 (en) * | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20220273659A1 (en) * | 2019-07-02 | 2022-09-01 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| US20230132667A1 (en) * | 2020-05-28 | 2023-05-04 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
| CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| EP4433061A4 (en) * | 2021-11-18 | 2025-09-03 | Onconova Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| JP2024540529A (ja) * | 2021-11-18 | 2024-10-31 | オンコノヴァ セラピューティクス， インコーポレイテッド | がんを処置するための方法および組成物 |
| WO2023230288A1 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024107955A1 (en) * | 2022-11-17 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| AU763839B2 (en) * | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| KR20020070520A (ko) * | 2000-01-27 | 2002-09-09 | 워너-램버트 캄파니 | 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체 |
| JP4064671B2 (ja) * | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| PL358271A1 (pl) * | 2000-03-06 | 2004-08-09 | Warner-Lambert Company | 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| BRPI0507852A (pt) | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| RU2007128961A (ru) * | 2004-12-30 | 2009-02-10 | 4 Аза Ип Ив (Be) | ПИРИДО(3,2-d)ПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ПОЛЕЗНЫЕ ДЛЯ КОНСЕРВАТИВНОГО ЛЕЧЕНИЯ |
| GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| US8232278B2 (en) * | 2005-06-24 | 2012-07-31 | Gilead Sciences, Inc. | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C |
| CN101395155A (zh) * | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| CA2659746A1 (en) | 2006-08-02 | 2008-02-07 | Temple University - Of The Commonwealth System Of Higher Education | Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof |
| BRPI0715566A2 (pt) | 2006-10-16 | 2013-07-02 | Gpc Biotech Inc | composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto |
| WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| US8889696B2 (en) | 2009-12-18 | 2014-11-18 | Temple University—Of the Commonwealth System of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof |
| CA2807498C (en) * | 2010-08-05 | 2017-02-07 | Temple University-Of The Commonwealth System Of Higher Education | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
-
2011
- 2011-07-21 CA CA2807498A patent/CA2807498C/en active Active
- 2011-07-21 EP EP11815012.7A patent/EP2600719B1/en active Active
- 2011-07-21 EA EA201390199A patent/EA022527B1/ru not_active IP Right Cessation
- 2011-07-21 AU AU2011286282A patent/AU2011286282B2/en not_active Ceased
- 2011-07-21 ES ES11815012.7T patent/ES2525866T3/es active Active
- 2011-07-21 PL PL11815012T patent/PL2600719T3/pl unknown
- 2011-07-21 PT PT118150127T patent/PT2600719E/pt unknown
- 2011-07-21 BR BR112013002375-9A patent/BR112013002375B1/pt active IP Right Grant
- 2011-07-21 CN CN201180038325.3A patent/CN103200822B/zh active Active
- 2011-07-21 MX MX2013001427A patent/MX2013001427A/es active IP Right Grant
- 2011-07-21 WO PCT/US2011/044807 patent/WO2012018540A1/en not_active Ceased
- 2011-07-21 US US13/813,023 patent/US8987267B2/en active Active
- 2011-07-21 KR KR1020137004979A patent/KR101434841B1/ko active Active
- 2011-07-21 JP JP2013523185A patent/JP5512894B2/ja not_active Expired - Fee Related
- 2011-07-21 DK DK11815012.7T patent/DK2600719T3/da active
- 2011-07-21 NZ NZ606281A patent/NZ606281A/en unknown
-
2013
- 2013-02-03 IL IL224555A patent/IL224555A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011286282A1 (en) | 2013-02-14 |
| IL224555A (en) | 2016-03-31 |
| EP2600719A1 (en) | 2013-06-12 |
| PL2600719T3 (pl) | 2015-03-31 |
| CA2807498C (en) | 2017-02-07 |
| CA2807498A1 (en) | 2012-02-09 |
| KR20130098314A (ko) | 2013-09-04 |
| EP2600719A4 (en) | 2014-01-01 |
| BR112013002375A2 (pt) | 2016-05-24 |
| US20130131058A1 (en) | 2013-05-23 |
| WO2012018540A1 (en) | 2012-02-09 |
| JP2013538196A (ja) | 2013-10-10 |
| DK2600719T3 (da) | 2014-12-15 |
| KR101434841B1 (ko) | 2014-08-29 |
| MX2013001427A (es) | 2013-06-13 |
| NZ606281A (en) | 2014-09-26 |
| CN103200822A (zh) | 2013-07-10 |
| AU2011286282B2 (en) | 2014-08-21 |
| EA022527B1 (ru) | 2016-01-29 |
| EP2600719B1 (en) | 2014-10-08 |
| US8987267B2 (en) | 2015-03-24 |
| JP5512894B2 (ja) | 2014-06-04 |
| PT2600719E (pt) | 2014-12-22 |
| ES2525866T3 (es) | 2014-12-30 |
| EA201390199A1 (ru) | 2013-07-30 |
| CN103200822B (zh) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013002375B1 (pt) | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto | |
| JP6511430B2 (ja) | がんの治療のための化合物および組成物 | |
| CN115894520A (zh) | 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用 | |
| HUE029275T2 (en) | Phthalazinone ketone derivative, method of preparation and therapeutic use | |
| JP7626721B2 (ja) | 小分子標的ブロモ／アセチルタンパク質およびその使用 | |
| CN106083849A (zh) | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 | |
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| JP5797664B2 (ja) | 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用 | |
| ES3056703T3 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| WO2017181974A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| ES2263033T3 (es) | Derivados de pirodoindolona sustituidos en posicion 3 con un grupo heterociclico, su preparacion y su aplicacion en terapeutica. | |
| ES2715348T3 (es) | Compuestos que contienen anillos de nitrógeno fusionados para su uso como antagonistas de CRTH2 | |
| WO2017181973A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| AU2010330863B2 (en) | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof | |
| RU2487121C2 (ru) | Соединения и способы модулирования киназ и показания к применению указанных соединений и способов | |
| WO2025119352A1 (zh) | 一种并环类mat2a抑制剂、包含其的药物组合物及其应用 | |
| JP6370772B2 (ja) | 化合物の調製のための中間体及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2011, OBSERVADAS AS CONDICOES LEGAIS. |